INFLIXIMAB DOSE-REDUCTION IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS IN PROLONGED DEEP REMISSION: POTENTIAL IMPLICATIONS ON DE-ESCALATION STRATEGIES IN A REAL LIFE CLINICAL SETTING WITHOUT A THERAPEUTIC DRUG MONITORING (TDM) APPROACH.

Andrea Buda    

Conference
UEG Week 2018


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at office@ueg.eu

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing